PTPRC and inflammatory bowel disease: Concerning subsets, we found a decrease of immature NCR− ILC3 in IBD patients as compared to HCs (24.00 vs. 30.90% of total ILC population, p = 0.02; 0.01 vs. 0.02% of total CD45+ cells, p < 0.001), whereas the proportion of ILC1 among ILCs in blood was increased in IBD patients (20.40 vs. 6.81%, p < 0.0001; Figures 2C–E).